Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Work In Process: 2022

  • Amylyx Pharmaceuticals' Work In Process was N/A to $1.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2022, Amylyx Pharmaceuticals' Work In Process is $1.7 million, which was up 3,635.56% from $45,000 recorded in Q3 2022.
  • In the past 5 years, Amylyx Pharmaceuticals' Work In Process registered a high of $1.7 million during Q4 2022, and its lowest value of $45,000 during Q3 2022.
  • Moreover, its 1-year median value for Work In Process was $863,000 (2022), whereas its average is $863,000.